Key Points
- Insider purchase: Director Michael Minogue bought 2,030 shares on Feb. 25 at an average price of $246.23 (total ~$499,847), increasing his stake to 17,483 shares — a 13.14% rise in ownership.
- Quarterly beat and growth: Insulet reported Q1 EPS of $1.55 versus $1.48 expected and revenue of $783.8M (up 31.2% year-over-year), showing stronger-than-expected results.
- Analyst sentiment: The consensus is a Moderate Buy (20 Buys, 3 Holds, 1 Sell) with an average price target of $354.57 and a market cap of about $17.7B.
Insulet Corporation (NASDAQ:PODD - Get Free Report) Director Michael Minogue acquired 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The stock was purchased at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the purchase, the director owned 17,483 shares of the company's stock, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Insulet Price Performance
Shares of NASDAQ:PODD opened at $251.50 on Friday. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. The company has a market cap of $17.71 billion, a PE ratio of 71.86, a price-to-earnings-growth ratio of 1.48 and a beta of 1.41. The company's 50 day moving average is $269.07 and its 200 day moving average is $303.58.
Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. The business had revenue of $783.80 million for the quarter, compared to the consensus estimate of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.15 EPS. On average, sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.
Wall Street Analysts Forecast Growth
PODD has been the topic of a number of recent research reports. Wolfe Research upped their target price on Insulet from $350.00 to $375.00 and gave the stock an "outperform" rating in a research note on Friday, November 7th. Zacks Research lowered shares of Insulet from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 5th. Truist Financial decreased their price objective on shares of Insulet from $390.00 to $360.00 and set a "buy" rating for the company in a research report on Thursday, February 19th. Citigroup lowered their target price on shares of Insulet from $380.00 to $345.00 and set a "buy" rating on the stock in a research note on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Insulet in a report on Thursday, January 22nd. Twenty equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $354.57.
View Our Latest Analysis on Insulet
Hedge Funds Weigh In On Insulet
A number of hedge funds have recently made changes to their positions in PODD. Larson Financial Group LLC boosted its stake in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in Insulet during the 4th quarter worth $26,000. Elyxium Wealth LLC acquired a new stake in Insulet during the 4th quarter worth $28,000. DV Equities LLC purchased a new stake in shares of Insulet during the fourth quarter worth $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet in the fourth quarter valued at about $29,000.
About Insulet
(
Get Free Report)
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
